DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00873223

CompletedPhase 1

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

33

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI ≤45•HbA1c 7-9.5%

Primary endpoint

•Insulin detemir pharmacokinetics with and without liraglutide administration

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00873223
Org study IDNN2211-3673

Timeline

Milestones

Study first posted2009-04-01estimated
Last update posted2017-01-26estimated
Study start2009-03 (month precision)
Primary completion2009-09actual (month precision)
Study completion2009-09actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosed with type 2 diabetes
•BMI less than 45.0 kg/m2
•Insulin naive
•Currently treated with Oral Anti-Diabetic drugs (OADs) and metformin with a HbA1c between 7.0 and 9.5% or currently treated with metformin only with a HbA1c between 7.0 and 10.0%

Exclusion criteria

•Any clinically significant disease other than type 2 diabetes
•Currently using daily insulin
•Thiazolidinione use or other injectable diabetes medications within the last 3 months

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Insulin detemir pharmacokinetics with and without liraglutide administration

Time frame:at approx. 12 weeks (including screening, washout and evaluation period)

concentration, descriptive

Secondary/protocol endpoint

Pharmacokinetics of liraglutide with and without insulin detemir

Time frame:at approx. 12 weeks (including screening, washout and evaluation period)

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.